Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic
- PMID: 34870090
- PMCID: PMC8637774
- DOI: 10.1177/25151355211059791
Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic
Abstract
Since the outbreak of the COVID-19 pandemic, there has been a rapid expansion in vaccine research focusing on exploiting the novel discoveries on the pathophysiology, genomics, and molecular biology of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Although the current preventive measures are primarily socially distancing by maintaining a 1 m distance, it is supplemented using facial masks and other personal hygiene measures. However, the induction of vaccines as primary prevention is crucial to eradicating the disease to attempt restoration to normalcy. This literature review aims to describe the physiology of the vaccines and how the spike protein is used as a target to elicit an antibody-dependent immune response in humans. Furthermore, the overview, dosing strategies, efficacy, and side effects will be discussed for the notable vaccines: BioNTech/Pfizer, Moderna, AstraZeneca, Janssen, Gamaleya, and SinoVac. In addition, the development of other prominent COVID-19 vaccines will be highlighted alongside the sustainability of the vaccine-mediated immune response and current contraindications. As the research is rapidly expanding, we have looked at the association between pregnancy and COVID-19 vaccinations, in addition to the current reviews on the mixing of vaccines. Finally, the prominent emerging variants of concern are described, and the efficacy of the notable vaccines toward these variants has been summarized.
Keywords: AstraZeneca; BioNTech/Pfizer; COVID-19 vaccine; Moderna; SARS-CoV-2 variants.
© The Author(s), 2021.
Conflict of interest statement
Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures


Similar articles
-
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877. Eur Rev Med Pharmacol Sci. 2021. PMID: 33629336 Review.
-
Role of COVID-19 Vaccines in SARS-CoV-2 Variants.Front Immunol. 2022 May 20;13:898192. doi: 10.3389/fimmu.2022.898192. eCollection 2022. Front Immunol. 2022. PMID: 35669787 Free PMC article. Review.
-
Adverse Effects of Pfizer (BioNTech), Oxford-AstraZeneca (ChAdOx1 CoV-19), and Moderna COVID-19 Vaccines among the Adult Population in Saudi Arabia: A Cross-Sectional Study.Vaccines (Basel). 2023 Jan 20;11(2):231. doi: 10.3390/vaccines11020231. Vaccines (Basel). 2023. PMID: 36851109 Free PMC article.
-
The COVID-19 pandemic: viral variants and vaccine efficacy.Crit Rev Clin Lab Sci. 2022 Jan;59(1):66-75. doi: 10.1080/10408363.2021.1979462. Epub 2021 Oct 1. Crit Rev Clin Lab Sci. 2022. PMID: 34598660 Review.
-
A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson.Hum Vaccin Immunother. 2022 Dec 31;18(1):2002083. doi: 10.1080/21645515.2021.2002083. Epub 2022 Feb 7. Hum Vaccin Immunother. 2022. PMID: 35130825 Free PMC article. Review.
Cited by
-
Serious events following COVID-19 vaccination with ChAdOx1 nCoV-19 vaccine (Vaxzevria): A short case series from Iran.Clin Case Rep. 2022 Feb 6;10(2):e05390. doi: 10.1002/ccr3.5390. eCollection 2022 Feb. Clin Case Rep. 2022. PMID: 35145690 Free PMC article.
-
Qualitative interviews to evaluate content validity of the ACTIV-2 COVID-19 Symptom Diary (ACSD).J Patient Rep Outcomes. 2023 Jan 31;7(1):8. doi: 10.1186/s41687-022-00535-x. J Patient Rep Outcomes. 2023. PMID: 36719546 Free PMC article.
-
An Update on Anti-COVID-19 Vaccines and the Challenges to Protect Against New SARS-CoV-2 Variants.Pathogens. 2025 Jan 1;14(1):23. doi: 10.3390/pathogens14010023. Pathogens. 2025. PMID: 39860984 Free PMC article. Review.
-
Autoimmune encephalitis after BBIBP-CorV (Sinopharm) COVID-19 vaccination: a case report.BMC Neurol. 2022 Nov 14;22(1):427. doi: 10.1186/s12883-022-02949-y. BMC Neurol. 2022. PMID: 36376863 Free PMC article.
-
Concomitant administration of seasonal influenza and COVID-19 mRNA vaccines.Emerg Microbes Infect. 2024 Dec;13(1):2292068. doi: 10.1080/22221751.2023.2292068. Epub 2024 Jan 18. Emerg Microbes Infect. 2024. PMID: 38054302 Free PMC article.
References
-
- Johns Hopkins University & Medicine. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Coronavirus Resource Center, Johns Hopkins University & Medicine, 2021, https://coronavirus.jhu.edu/map.html
-
- McCormick LC, Benhamou M, Pogkas D. The Covid-19 pandemic has added $19.5 trillion to global debt. Bloomberg, 27 January 2021, https://www.bloomberg.com/graphics/2021-coronavirus-global-debt/#:~:text...
-
- WHO. COVID-19 vaccine tracker and landscape, 2021, https://www.who.int/publications/m/item/draft-landscape-of-covid-19-cand...
-
- Krammer F. SARS-CoV-2 vaccines in development. Nature 2020; 586(7830): 516–527. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous